Top 10 Private Equity Investors: Biotechnology/LifeSciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | Eli Lilly and Company |
| 3 | Casdin Capital |
| 4 | Janus Henderson Investors |
| 5 | Redmile Group |
| 6 | Bristol-Myers Squibb |
| 7 | A&Z Pharmaceuticals |
| 8 | Wellington Management |
| 9 | T. Rowe Price Group |
| 10 | Cormorant Asset Management |
Crossover funds that moved down from public markets appear alongside the traditional buyout franchises. Clinical data readouts and large pharma acquisition appetite set the pace of investment across biotech, with capital concentrating in firms that can underwrite science. These are buyers and control investors. This list is most relevant if you are selling the company, recapitalizing, or seeking a majority partner.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.